US 10,702,560 B2Granted

Antibiotic sensitive Bacillus strains having antimicrobial effect against E. coli and Clostridium perfringens and having high sporulation capacity

AssigneeChr. Hansen A/S

InventorsBeatrice Nielsen, Mette Dines Cantor, Birgitte Stuer-Lauridsen, Patrick Derkx, Eric Johansen

Life of this patent

Estimating the term…

Loading patent…

Abstract

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

Claims20

Dependent claims

A probiotic animal feed or animal feed premix composition with improved resistance to growth of Escherichia coli (E. coli) and Clostridium perfringens, comprising

(a) from 105 to 1012 CFU/g of one or more Bacillus strains that exhibit (i) sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol;
(ii) antimicrobial activity against E. coli and Clostridium perfringens;
and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation, and
(b) one or more animal feed or animal feed premix ingredients,
wherein at least one of the one or more Bacillus strains is selected from:
(a) Bacillus mojavensis strain CHCC 15510 deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Inhoffenstrasse 7B, D-38124 Braunschweig, Germany (DSMZ) under accession number DSM 25839;
(b) Bacillus amyloliquefaciens strain CHCC 15516 deposited with DSMZ under accession number DSM 25840;
(c) Bacillus amyloliquefaciens strain CHCC 15536 deposited with DSMZ under accession number DSM 27032;
(d) Bacillus amyloliquefaciens strain CHCC 15539 deposited with DSMZ under accession number DSM 27033;
and (e) Bacillus subtilis strain CHCC 15541 deposited with DSMZ under accession number DSM 25841, and
wherein the one or more Bacillus strains are effective to inhibit growth of E. coli and Clostridium perfringens.

8 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/836,346Filed 8 Dec 2017 · division
Priority: EP 1216408713 Apr 2012
Published: US 2018/0200309 A119 Jul 2018
Granted: 7 Jul 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 35/742
Probiotics: spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
A23K 10/18
Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions: of live microorganisms
C12N 1/20
Microorganisms; Compositions thereof ; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of…:…
C12N 1/205
Bacteria; Culture media therefor: bacterial isolates

Family

PCT/EP2013/057590Parent of this division · filed 11 Apr 2013
US 2018/0200309 A1Pre-grant publication · published 19 Jul 2018
Application14/391,564Parent of this division
US 9,844,573 B2Parent of this division
US 2015/0079058 A1Published application
US 10,702,560 B2This patent

From the US filing history. Foreign family members aren’t listed.